Heather H Cheng1,2, Melissa Plets1, Hongli Li1, Celestia S Higano1,2, Catherine M Tangen1, Neeraj Agarwal3, Nicholas J Vogelzang4, Maha Hussain5, Ian M Thompson6, Muneesh Tewari7, Evan Y Yu1,2. 1. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington. 2. Division of Medical Oncology, University of Washington, Seattle, Washington. 3. Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. 4. US Oncology, Las Vegas, Nevada. 5. Northwestern University, Feinberg School of Medicine, Chicago, Illinois. 6. CHRISTUS Santa Rosa Medical Center Hospital, San Antonio, Texas. 7. Departments of Internal Medicine and Biomedical Engineering, Center for Computational Medicine and Bioinformatics, Biointerfaces Institute, University of Michigan, Ann Arbor, Michigan.
Abstract
BACKGROUND: Previous studies suggest circulating, blood-based microRNAs (miRNAs) may serve as minimally invasive prostate cancer biomarkers, however there is limited data from prospective clinical trials. Here, we explore the role of candidate plasma miRNAs as potential biomarkers in the SWOG 0925 randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. METHODS: Correlative biospecimens, including circulating tumor cells (CTCs) and plasma for miRNA analysis, were collected at baseline and after 12 weeks on treatment from 50 patients enrolled on SWOG 0925. Circulating microRNAs were quantified using real-time RT-PCR microRNA array that allowed specific analysis of previously identified candidate miRNAs (miR-141, miR-200a, miR-200b, miR-210, and miR-375) as well as discovery analysis to identify new candidate miRNAs. MiRNA levels were correlated to previously reported CTC counts using CellSearch® (Veridex) and with the primary study outcome of 28-week PSA response (≤0.2, 0.2 to ≤4.0, or >4.0 ng/mL), previously shown to correlate with overall survival. RESULTS: We observed a correlation between baseline circulating miR-141, miR-200a, and miR-375 levels with baseline CTCs. Baseline miR-375 levels were associated with 28-week PSA response (≤0.2, 0.2 to ≤4.0, or >4.0 ng/mL, P = 0.007). Using ROC curve analysis, there was no significant difference between baseline miR-375 and baseline CTC in predicting 28-week PSA response (≤0.2 vs >0.2 ng/mL). To discover novel candidate miRNAs, we analyzed 365 miRNAs for association with the 28-week PSA response endpoint and identified new candidate miRNAs along with the existing candidates miR-375 and miR-200b (P = 0.0012, P = 0.0046, respectively. CONCLUSIONS:Baseline plasma miR-141, miR-200a, and miR-375 levels are associated with baseline CTC count. Baseline miR-375 was also associated with the trial endpoint of 28-week PSA response. Our results provide evidence that circulating miRNA biomarkers may have value as prognostic biomarkers and warrant further study in larger prospective clinical trials.
RCT Entities:
BACKGROUND: Previous studies suggest circulating, blood-based microRNAs (miRNAs) may serve as minimally invasive prostate cancer biomarkers, however there is limited data from prospective clinical trials. Here, we explore the role of candidate plasma miRNAs as potential biomarkers in the SWOG 0925 randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. METHODS: Correlative biospecimens, including circulating tumor cells (CTCs) and plasma for miRNA analysis, were collected at baseline and after 12 weeks on treatment from 50 patients enrolled on SWOG 0925. Circulating microRNAs were quantified using real-time RT-PCR microRNA array that allowed specific analysis of previously identified candidate miRNAs (miR-141, miR-200a, miR-200b, miR-210, and miR-375) as well as discovery analysis to identify new candidate miRNAs. MiRNA levels were correlated to previously reported CTC counts using CellSearch® (Veridex) and with the primary study outcome of 28-week PSA response (≤0.2, 0.2 to ≤4.0, or >4.0 ng/mL), previously shown to correlate with overall survival. RESULTS: We observed a correlation between baseline circulating miR-141, miR-200a, and miR-375 levels with baseline CTCs. Baseline miR-375 levels were associated with 28-week PSA response (≤0.2, 0.2 to ≤4.0, or >4.0 ng/mL, P = 0.007). Using ROC curve analysis, there was no significant difference between baseline miR-375 and baseline CTC in predicting 28-week PSA response (≤0.2 vs >0.2 ng/mL). To discover novel candidate miRNAs, we analyzed 365 miRNAs for association with the 28-week PSA response endpoint and identified new candidate miRNAs along with the existing candidates miR-375 and miR-200b (P = 0.0012, P = 0.0046, respectively. CONCLUSIONS: Baseline plasma miR-141, miR-200a, and miR-375 levels are associated with baseline CTC count. Baseline miR-375 was also associated with the trial endpoint of 28-week PSA response. Our results provide evidence that circulating miRNA biomarkers may have value as prognostic biomarkers and warrant further study in larger prospective clinical trials.
Authors: Emmanuel S Antonarakis; Changxue Lu; Brandon Luber; Hao Wang; Yan Chen; Yezi Zhu; John L Silberstein; Maritza N Taylor; Benjamin L Maughan; Samuel R Denmeade; Kenneth J Pienta; Channing J Paller; Michael A Carducci; Mario A Eisenberger; Jun Luo Journal: J Clin Oncol Date: 2017-04-06 Impact factor: 44.544
Authors: Amir Goldkorn; Benjamin Ely; David I Quinn; Catherine M Tangen; Louis M Fink; Tong Xu; Przemyslaw Twardowski; Peter J Van Veldhuizen; Neeraj Agarwal; Michael A Carducci; J Paul Monk; Ram H Datar; Mark Garzotto; Philip C Mack; Primo Lara; Celestia S Higano; Maha Hussain; Ian Murchie Thompson; Richard J Cote; Nicholas J Vogelzang Journal: J Clin Oncol Date: 2014-03-10 Impact factor: 50.717
Authors: Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: Akira Watahiki; Robyn J Macfarlane; Martin E Gleave; Francesco Crea; Yuzhuo Wang; Cheryl D Helgason; Kim N Chi Journal: Int J Mol Sci Date: 2013-04-10 Impact factor: 5.923
Authors: Heather H Cheng; Patrick S Mitchell; Evan M Kroh; Alexander E Dowell; Lisly Chéry; Javed Siddiqui; Peter S Nelson; Robert L Vessella; Beatrice S Knudsen; Arul M Chinnaiyan; Kenneth J Pienta; Colm Morrissey; Muneesh Tewari Journal: PLoS One Date: 2013-07-30 Impact factor: 3.240
Authors: Julia M A Pickl; Diana Tichy; Vladimir Y Kuryshev; Yanis Tolstov; Michael Falkenstein; Julia Schüler; Daniel Reidenbach; Agnes Hotz-Wagenblatt; Glen Kristiansen; Wilfried Roth; Boris Hadaschik; Markus Hohenfellner; Stefan Duensing; Doreen Heckmann; Holger Sültmann Journal: Oncotarget Date: 2016-09-13
Authors: Esther Campos-Fernández; Letícia S Barcelos; Aline Gomes de Souza; Luiz R Goulart; Vivian Alonso-Goulart Journal: Am J Cancer Res Date: 2019-07-01 Impact factor: 6.166
Authors: Monyse de Nóbrega; Mariana Bisarro Dos Reis; Érica Romão Pereira; Marilesia Ferreira de Souza; Ilce Mara de Syllos Cólus Journal: J Cancer Res Clin Oncol Date: 2022-08-04 Impact factor: 4.322
Authors: Emmy Boerrigter; Guillemette E Benoist; Inge M van Oort; Gerald W Verhaegh; Onno van Hooij; Levi Groen; Frank Smit; Irma M Oving; Pieter de Mol; Tineke J Smilde; Diederik M Somford; Niven Mehra; Jack A Schalken; Nielka P van Erp Journal: Mol Oncol Date: 2021-05-29 Impact factor: 6.603